Deals this week: Marina Biotech, Strekin, H. Lundbeck

8th June 2017 (Last Updated June 8th, 2017 18:30)

Marina Biotech has acquired Prestalia, a drug indicated for the treatment of hypertension to low blood pressure from Symplmed Pharmaceuticals.

Marina Biotech has acquired Prestalia, a drug indicated for the treatment of hypertension to low blood pressure from Symplmed Pharmaceuticals.

Both companies involved in the transaction are based in the US.

Strekin has completed a seed C financing round from private investors to raise funds to conduct a second clinical trial of STR001 as a potential new treatment for acute types of hearing loss.

Based in Switzerland, the clinical-stage biopharmaceutical company has raised Sfr10m ($10.4m) through the round from investors.

The Lundbeck Foundation’s pharmaceutical subsidiary, H. Lundbeck, has signed a research agreement with ImmunoBrain Checkpoint (IBC).

"Strekin has completed a seed C financing round from private investors to raise funds to conduct a second clinical trial of STR001 as a potential new treatment for acute types of hearing loss."

Lundbeck will fund and participate IBC’s research in the treatment of Alzheimer’s disease to identify drug candidates for clinical testing as part of the agreement.

AbCellera Biologics and Sanofi Pasteur have announced a research partnership, under which Sanofi will profile vaccine-specific human antibodies elicited by seasonal influenza vaccination using AbCellera’s single-cell screening platform.

The platform will also be used to generate panels of human monoclonal antibodies with desired binding profiles to influenza strains.

Both companies involved in the partnership are based in Canada.

BlackThorn Therapeutics and Mindstrong Health have signed an agreement for research on the treatment of neurobehavioural disorders.

Both companies involved in the transaction are US-based biopharmaceutical firms.